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How MYC promotes the development of cancer re-
mains to be fully understood. Here, we report that
the Zn2+-finger transcription factor ASCIZ (ATMIN,
ZNF822) synergizes with MYC to activate the expres-
sion of dynein light chain (DYNLL1, LC8) in themurine
Em-Myc model of lymphoma. Deletion of Asciz or
Dynll1 prevented the abnormal expansion of pre-B
cells in pre-cancerous Em-Mycmice and potentiated
the pro-apoptotic activity of MYC in pre-leukemic
immature B cells. Constitutive loss of Asciz or Dynll1
delayed lymphoma development in Em-Myc mice,
and induced deletion of Asciz in established lym-
phomas extended the survival of tumor-bearing
mice. We propose that ASCIZ-dependent upregula-
tion of DYNLL1 levels is essential for the develop-
ment and expansion of MYC-driven lymphomas by
enabling the survival of pre-neoplastic andmalignant
cells.INTRODUCTION
Members of the MYC family of helix-loop-helix transcription fac-
tors are deregulated in the majority of human cancers (Vita and
Henriksson, 2006), including various B cell lymphoma subtypes
(Ott et al., 2013). MYC levels are extremely low in quiescent cells,
and limiting in cycling cells, but at abnormally high oncogenic
levels, MYC can bind to virtually all active gene promoters
(Wolf et al., 2015). In this way, MYC is believed to globally amplify
the signal of other promoter-bound transcriptional activators and
repressors in amanner that promotes cellular transformation and
tumorigenesis. The mechanisms by which it does this remain
incompletely understood (Wolf et al., 2015).
Studies of Em-Myc mice, which carry a transgene mimicking
the t(8;14) chromosomal translocation between an Igh enhancer1488 Cell Reports 14, 1488–1499, February 16, 2016 ª2016 The Authand the Myc oncogene that is characteristic of human Burkitt
lymphoma, have provided substantial insight into how MYC
overexpression promotes tumor development (Adams et al.,
1985). In Em-Myc mice, MYC is overexpressed in the B cell
lineage and causes highly penetrant clonal B cell lymphomas
(with predominantly surface-IgM [immunoglobulin M]-negative
[sIgM] pre-B or sIgM+ immature B cell subtypes), with a median
latency of 110–120 days (Adams et al., 1985; Harris et al., 1988;
Mori et al., 2008). During the pre-leukemic phase, Em-Myc leads
to elevated numbers of cycling pre-B cells in the bone marrow
(Langdon et al., 1986). This is initially offset by increased
apoptosis (Cory et al., 1999), which is due, in part, to direct tran-
scriptional upregulation of the pro-apoptotic protein BIM by
MYC (Lee et al., 2013; Muthalagu et al., 2014). However, random
mutations that collaborate with Myc overexpression eventually
tip the balance against apoptosis, which results in uncontrolled
proliferation and the emergence of lymphoma (Cory et al.,
1999; Egle et al., 2004; Eischen et al., 1999; Kelly et al., 2011).
Consistently, the development of B cell lymphoma in Em-Myc
mice is dramatically accelerated by deletion of pro-apoptotic
genes such as Bim or p53 (Egle et al., 2004; Michalak et al.,
2009).
Recently, we found that the Zn2+-finger transcription factor
ASCIZ (also known as ATMIN or ZNF822) plays an important
role in normal B cell development by activating the expression
of the multi-functional protein DYNLL1. DYNLL1, in turn, re-
strains the pro-apoptotic action of BIM at the immature B cell
stage in the bone marrow. Conditional deletion of Asciz (on the
C57BL/6 background) in hematopoietic stem/progenitor cells
using Mx1-Cre, or in the B cell lineage using Mb1-Cre, led to
the progressive loss of pre-B and immature B cells in the bone
marrow and marked B lymphopenia in the periphery (Jurado
et al., 2012b). Normal development of Asciz-deleted B cells
could be restored by ectopic Dynll1 expression or by knockout
(KO) of the pro-apoptotic DYNLL1 target BIM (Jurado et al.,
2012b). A similar but milder B cell developmental defect was
also reported for Cd19-Cre Asciz-deleted mice (on a mixed ge-
netic background) (Loizou et al., 2011). Surprisingly, in contrastors
to Mx1-Cre or Mb1-Cre Asciz-deleted mice (Jurado et al.,
2012b), 40% of these Cd19-Cre Asciz-deleted mice were re-
ported to develop mature, peripheral B cell lymphomas. This
was presumably due to aberrant repair of activation-induced
deaminase (AID)-generated DNA breaks in germinal center B
cells. The emergence of B cell lymphomas in the Cd19-Cre As-
ciz-deleted mice prompted the postulate that ASCIZ functions
as a tumor suppressor (Loizou et al., 2011).
Here, we examined the roles of ASCIZ and DYNLL1 in lympho-
magenesis and sought to resolve whether the discrepant lym-
phoma incidence in the different conditional Asciz KO lines is
related to the timing of Cre recombinase induction during B
cell development. We found that Asciz deletion after completion
of B cell development in the bone marrow, but before peripheral
B cells reach full maturity, supports normal B cell homeostasis
without increased lymphoma risk. Moreover, we show that,
rather than being a tumor suppressor, ASCIZ is, in fact, essential
for lymphoma development originating from B cell precursors in
the Em-Myc mouse model.
RESULTS
ASCIZ Is Not Required for Mature B Cell Homeostasis
and Suppression of Peripheral B Cell Lymphomas
Despite qualitatively similar B cell developmental defects,
naive Cd19-Cre Asciz-deleted mice contained normal mature
B cell numbers in the spleen and blood (Loizou et al., 2011),
whereas Mx1-Cre or Mb1-Cre Asciz-deleted mice exhibited
a marked peripheral B lymphopenia (Jurado et al., 2012b).
Lower B cell numbers in Mx1-Cre or Mb1-Cre Asciz-deleted
mice would be expected to stochastically reduce the risk of
lymphoma development, compared to the Cd19-Cre Asciz-
deleted line. To test this hypothesis and study mature B cell
functions without the sequelae of an underlying developmental
defect, we used Cd23-Cre to delete Asciz. Cd23-Cre is acti-
vated during the transitional B cell stage in the periphery, after
completion of bone marrow B cell developmental stages,
but before follicular B cells have reached sufficient maturity
to activate mutagenic AID expression in germinal centers
(Kwon et al., 2008). In contrast to the 8-fold-lower (p <
0.0001) peripheral B cell numbers in Mb1-Cre Asciz-deleted
mice, B cell numbers in the spleens of Cd23-Cre Asciz-deleted
mice were indistinguishable from those in Cd23-Cre littermate
controls (Figure 1A). Furthermore, we found that serum levels
of the B cell survival factor BAFF were increased by 4-fold
(p < 0.0001) in Mb1-Cre Asciz-deleted mice (Figure 1B). This
would be expected to extend the lifespan of peripheral B cells
and thereby to partially compensate for lower B cell produc-
tion in the bone marrow (Vincent et al., 2013). In contrast,
BAFF serum concentrations were normal in Cd23-Cre Asciz-
deleted mice (Figure 1B). We confirmed that Asciz was effi-
ciently deleted by Cd23-Cre via PCR genotyping of mature
splenic B cells (IgM+ IgDhigh) and western blot analysis, using
loss of DYNLL1 as a surrogate marker for loss of ASCIZ (Fig-
ures 1E and 1F). Thus, the combination of normal B cell
numbers without increased BAFF levels indicates that ASCIZ
is not intrinsically required for the homeostasis of mature pe-
ripheral B lymphocytes.Cell RAfter establishing that their B cell numbers were normal, we
monitored the survival of Cd23-Cre Asciz-deleted mice over a
90-week period. B cell lymphomagenesis in the Cd19-Cre Asciz
model has been proposed to involve AID-dependent mutagen-
esis in peripheral B cells (Loizou et al., 2011), so we repeatedly
immunized our mice with sheep red blood cells to increase the
likelihood of ‘‘collateral’’ AID-induced DNA damage. However,
this did not lead to any tumor-related deaths in Cd23-Cre
Asciz-deleted mice up to 90 weeks of age (Figure 1G, blue stip-
pled line). All mouse spleen sections at this endpoint revealed an
unremarkable architecture typical of old immunized mice and
similar to the Cd23-Cre control (Figures S1G and S1H).
To increase the sensitivity of the model, we crossed the Cd23-
Cre Ascizmice with congenic Im-Bcl6 knockin mice. The Im-Bcl6
line develops diffuse large B cell lymphomas (DLBCL) with high
penetrance (>60%) but long latency (15–18 months) in an AID-
dependent manner (Cattoretti et al., 2005; Pasqualucci et al.,
2008). If ASCIZ functioned as a tumor suppressor of peripheral
AID-dependent lymphomas, we would predict that Cd23-Cre
Asciz deletion should accelerate tumorigenesis in Im-Bcl6 mice.
Im-Bcl6 control mice succumbed to lymphomas with the ex-
pected incidence and long latency (Figures 1G and 1H). How-
ever, neither the time of onset of terminal disease nor the
incidence of indolent lymphoma in the surviving 90-week-old
mice was significantly affected by loss of ASCIZ (Figures 1G,
1H, and S1I–S1L). Collectively, these data demonstrate that AS-
CIZ does not act as a cell-intrinsic tumor suppressor in mature
peripheral B cells.
ATM Signaling Is Not Impaired in ASCIZ-Deficient
Mature B Cells
The increased B cell lymphoma incidence in Cd19-Cre Asciz-
deleted mice has been attributed to increased genome instability
due to impaired ataxia telangiectasia mutated (ATM) signaling in
mature B cells (Loizou et al., 2011). Tomonitor genome instability,
we purified splenic B cells from Cd23-Cre control and Cd23-Cre
Asciz-deleted mice and stimulated them for 3 days with CD40
ligand, interleukin-4 (IL4), and lipopolysaccharide (LPS). In con-
trast to very high levels of chromosome breaks reported in
Cd19-Cre Asciz-deleted mice under similar conditions (Loizou
et al., 2011), we did not observe increased genome instability in
metaphase chromosome spreads of Cd23-Cre Asciz-deleted
mature B cells, compared to the Cd23-Cre control (Figures
S1D–S1F). We also found that canonical activation of ATM, and
phosphorylation of its targets KAP1 and p53 in response to
ionizing radiation,was not affected in ASCIZ-deficient B cells (Fig-
ure S1A) or fibroblasts (Figure S1B). We did not observe signifi-
cant non-canonical activation of ATM by low-salt treatment in
stimulated B cells—in contrast to fibroblasts treated in parallel
(Figure S1B). However, phosphorylation of KAP1 was slightly
increased in Asciz-deleted B cells compared to the control (Fig-
ure S1A). PCR genotyping and loss of DYNLL1 expression on
western blots confirmed thatAscizwas efficiently deleted in these
B cell cultures (Figures S1A and S1C).
We also monitored the generation of immunoglobulin (Ig)
class-switched antibodies as an in vivomarker for ATM functions
in mature B cells (Reina-San-Martin et al., 2004). Serum titers of
antigen-specific IgG1-switched antibodies were significantlyeports 14, 1488–1499, February 16, 2016 ª2016 The Authors 1489
Figure 1. Normal B Cell Homeostasis, Func-
tions, and Lymphoma Incidence inCd23-Cre
Asciz-Deleted Mice
(A) Splenic B cell numbers inMb1-Cre control (n =
8) and Asciz-deleted mice (n = 8) and in Cd23-Cre
control (n = 4) and Asciz-deleted mice (n = 6).
(B) SerumBAFF level inMb1-Cre control (n = 4) and
Asciz-deleted mice (n = 5) and in Cd23-Cre control
(n = 4) and Asciz-deleted mice (n = 5).
(C and D) ELISAs of high-affinity (NP2) and total
(NP14) antigen-specific serum IgG1 titers of Mb1-
Cre Asciz (C) and Cd23-Cre Asciz (D) mice 13 days
after immunization with NP-KLH.
(E) PCR analysis of Asciz deletion in FACS-sorted
transitional stage 1 (T1) (IgM+IgDlow), transitional
stage 2 (T2)/mature (IgM+IgDhi), and NP2-reactive
IgG1-switched B cells from Cd23-Cre Ascizfl/fl and
Cd23-Cre control mice compared to tail DNA from
the samemice 13 days after immunization with NP-
KLH. WT, wild-type.
(F) Western blot analysis of FACS-purified mature
splenic B cells (IgMlow IgDhigh) from a Cd23-Cre
control and a Cd23-Cre Asciz-deleted mouse
probed with DYNLL1 (as a surrogate marker for the
presence of ASCIZ) and GAPDH (as a loading
control) antibodies.
(G) Survival curves forCd23-Cre control,Cd23-Cre
Asciz-deleted, Cd23-Cre Im-Bcl6 control, and
Cd23 Im-Bcl6 Asciz-deleted mice. Arrows indicate
times of intraperitoneal injectionwith 108 sheep red
blood cells (SRBC) in 100 ml PBS.
(H) Incidence of DLBCL (black), lymphoid hyper-
plasia (gray) or normal architecture in surviving
mice at 90 weeks (white).
Error bars represent mean ± SEM.reduced in immunizedMb1-Cre Asciz-deleted mice (Figure 1C),
proportional to their reduction in mature B cell numbers. In
contrast, the generation of both total and high-affinity, antigen-
specific IgG1-switched antibodies was normal in Cd23-Cre
Asciz-deleted mice (Figure 1D). PCR genotyping confirmed
that Asciz was efficiently deleted by Cd23-Cre in FACS-sorted
IgG1-switched, antigen-specific B cells under these conditions
(Figure 1E).1490 Cell Reports 14, 1488–1499, February 16, 2016 ª2016 The AuthorsCollectively, these results indicate that
ASCIZ is not directly required for ATM
activation and ATM-dependent mainte-
nance of genome stability in activated
mature B cells in vitro or for the ATM-
dependent processing of AID-mediated
DNA breaks in antigen-stimulated B cells
in vivo.
Loss of ASCIZ Prevents the
Development of Bone Marrow-
DerivedBCell Lymphoma inEm-Myc
Mice
ASCIZ is critical for pre-B and immature B
cell development stages in the bone
marrow (Jurado et al., 2012b). To deter-
mine whether ASCIZ affects the develop-ment of lymphomas originating from these stages of B lympho-
cyte differentiation, we intercrossed the Mb1-Cre Asciz line
with congenic Em-Myc mice. Em-Myc mice are predisposed to
develop pre-B and immature B cell lymphomas (Adams et al.,
1985; Mori et al., 2008). As expected (Harris et al., 1988), Mb1-
Cre Em-Myc control mice developed B cell lymphomas with an
average latency of 117 days (Figure 2A). Remarkably, disease
onset was dramatically suppressed in the absence of ASCIZ:
Figure 2. Loss of ASCIZ Suppresses LymphomaDevelopment inEm-
Myc Mice
(A) Survival analysis of Mb1-Cre Asciz+/+ Em-Myc mice (red) and Mb1-Cre
Ascizfl/fl Em-Myc mice (blue).
(B) FACS immunophenotyping of four rare remaining Em-Myc lymphomas in
Mb1-Cre Asciz-deleted mice.
(C) Fractional distribution of surface IgM+ and surface IgM lymphomas in
control and Asciz-deleted Em-Myc mice.
(D) Western blot analysis of the four Asciz-deleted Em-Myc lymphomas from
(C) compared to normal Mb1-Cre control and Mb1-Cre Asciz-deleted splenic
B cells. Asterisk denotes a cross-reacting band (that does not correspond to
any possible partial Cre-lox recombination product), and ^ denotes the pre-
pro-B cell-like lymphoma from (C), which corresponds to a developmental
stage before Mb1-Cre is normally expressed.
Cell Rwhereas >80% of Em-Myc control mice died from lymphoma,
<20% of Asciz-deleted Em-Myc mice developed lymphoma
during an 8-month observation period (Figure 2A; p < 0.0001).
Surface marker analysis of the rare lymphomas that still arose
in the absence of ASCIZ revealed a range of B cell lymphoma
subtypes, which did not differ from the Em-Myc control cohort
(Figures 2B and 2C). Western blot analysis confirmed the loss
of ASCIZ in most of these lymphomas, except in one pre-pro-
B cell-like lymphoma (#3 in Figures 2B and 2D), which is con-
sistent with the notion that Mb1-Cre is not active until the
subsequent pro-B cell stage (Hobeika et al., 2006). Em-Myc
mice represent, arguably, the most widely studied animal model
used to understand genetic mechanisms of B cell lymphoma-
genesis. Numerous mutations have been reported to accelerate
the development of lymphoma in these mice; e.g., loss of Arf
(Eischen et al., 1999), Bim (Egle et al., 2004), p53 (Michalak
et al., 2009), or Atm (Shreeram et al., 2006). However, only rela-
tively fewmutations—e.g., loss ofBcl-xl (Kelly et al., 2011), eIF4F
(Lin et al., 2012), or Moz1 (Sheikh et al., 2015)—have been
reported to delay lymphoma development in Em-Myc mice,
and the protective effect of Asciz deletion that we show here
is more profound than any previously published genetic
intervention.
Loss of ASCIZ Is Synthetic Lethal with MYC
Overexpression in Pre-leukemic B Lymphoid
Progenitors
We measured the numbers of pre-leukemic B lymphoid cells in
tumor-free 8-week-old mice in order to explore the underlying
mechanism of the protective effect of Asciz deletion on lympho-
magenesis. MYC overexpression led to the expected (Langdon
et al., 1986; Strasser et al., 1996) 3-fold increase in pre-B cell
numbers in the bone marrow compared to the Mb1-Cre control
(Figures 3A and 3B; p = 0.0001). Interestingly, the number of pre-
B cells in Em-Myc DAsciz double mutants was reduced by
7.5-fold compared to Em-Myc mice (Figures 3A and 3B; p <
0.001) and was similar to the low level observed in Mb1-Cre
Asciz-deleted mice. Most strikingly, whereas immature B cell
numbers were reduced by 10-fold in Mb1-Cre Asciz-deleted
mice compared to the Mb1-Cre and Em-Myc controls (Figures
3A and 3B; p < 0.0001), this reduction was exacerbated to
60-fold lower than control levels in Em-Myc DAsciz double mu-
tants (Figures 3A and 3B; p < 0.0001).
Loss of ASCIZ and MYC overexpression both led to increased
apoptosis at the immature B cell stage (Jurado et al., 2012b;
Strasser et al., 1996). Therefore, we tested whether a synergistic
interaction between the two mutations could be the reason for
the near-complete elimination of immature B cells in Em-Myc
DAsciz double mutants (Figure 3B). As expected (Jurado et al.,
2012b; Strasser et al., 1996), cell death was increased by 2-
fold in Mb1-Cre Asciz-deleted (Figures 3C and 3D; p = 0.0066)
or Em-Myc (Figures 3C and 3D; p = 0.0071) single-mutant imma-
ture B cells compared to control mice. However, this was
increased by 15-fold in the few remaining Em-Myc DAsciz dou-
ble-mutant immature B lymphocytes (Figures 3C and 3D; p <
0.0001). Collectively, these data indicate that loss of Asciz pre-
vents lymphoma development by potentiating the pro-apoptotic
action of Em-Myc in pre-leukemic immature B cells, as well as byeports 14, 1488–1499, February 16, 2016 ª2016 The Authors 1491
Figure 3. Synthetic-Lethal Interaction be-
tween Asciz Deficiency and Oncogenic
MYC Deregulation in Pre-leukemic B Cell
Precursors
(A) FACS plots of bone marrow cell suspensions
of Mb1-Cre control, Mb1-Cre Asciz-deleted,
Mb1-Cre Em-Myc control, and Mb1-Cre Em-Myc
Asciz-deleted mice, with the immature B cell gate
highlighted. Gating strategies are shown in Fig-
ure S2.
(B) Enumeration of B lymphoid fractions in the
bone marrow (per leg) and B220+ IgM+ cells in the
spleen.Mb1-Cre control (n = 13),Mb1-Cre DAsciz
(n = 12 or 13), Mb1-Cre Em-Myc (n = 12 or 13),
and Mb1-Cre Em-Myc DAsciz (n = 7). p values
were omitted from the graph for clarity. Pro-B/pre-
B cells: Em-Myc versus control, p = 0.0001; Em-Myc
versus all others, p < 0.001; DAsciz versus con-
trol, p = 0.0011. Immature B cells: DAsciz versus
all others, p < 0.0001; Em-Myc DAsciz versus all
others, p < 0.0001. Spleen: DAsciz versus
all others, p < 0.0001; Em-Myc DAsciz versus all
others, p < 0.0001.
(C) FACS plots of B220+ IgM+ IgD-gated imma-
ture B cells stained with 7-AAD and annexin-V.
(D) Quantification of cell death (7AAD+ AnnV+ cells)
in pre-B and immature B cells of Mb1-Cre control
(n = 9), Mb1-Cre DAsciz (n = 7), Mb1-Cre Em-Myc
(n = 9), Mb1-Cre Em-Myc DAsciz (n = 4) mice. p
values were omitted for clarity. Immature B cells:
DAsciz versus control, p = 0.0066; Em-Myc versus
control, 0.0071; Em-Myc DAsciz versus all others,
p < 0.0001.
Error bars represent mean ± SEM.
See also Figure S2.antagonizing the pre-malignant expansion of pre-B cells in Em-
Myc mice.
ASCIZ Is Required forMYC-Dependent Hyper-activation
of DYNLL1 Expression in Pre-leukemic B Cell
Precursors
Loss of ASCIZ invariably leads to dramatically reduced DYNLL1
levels in all cell types studied to date, from Drosophila to hu-
mans (Goggolidou et al., 2014; Jurado et al., 2012a, 2012b;
Zaytseva et al., 2014). Surprisingly, and in contrast to non-
cancerous Mb1-Cre Asciz-deleted splenic B cells, we noticed
that, in all bona fide Asciz-deleted Em-Myc lymphomas,
DYNLL1 protein was maintained at high levels comparable to
that of control B cells (Figure 2D). Thus, to determine how
MYC overexpression affects DYNLL1 levels in the presence
or absence of ASCIZ, we FACS-purified (B220+ CD19+ IgM)
pooled pro-B/pre-B cells from pre-malignant 8-week-old
mice. As expected, DYNLL1 was essentially undetectable in
Asciz-deleted pro-B/pre-B cells (Figure 4A), underscoring the
efficiency of Mb1-Cre at these early stages of B cell develop-
ment (Hobeika et al., 2006). Strikingly, DYNLL1 levels in Mb1-
Cre Em-Myc pro-B/pre-B cells were upregulated by >6-fold
compared to Mb1-Cre control cells (Figure 4A), and this was
reversed to near-normal control levels in Em-Myc DAsciz cells
(Figure 4A). This level of DYNLL1 upregulation was substantially
higher than the well-established (Egle et al., 2004) 2-fold up-1492 Cell Reports 14, 1488–1499, February 16, 2016 ª2016 The Authregulation of BIM in pre-malignant Em-Myc B cell precursors
(Figure 4A) or the 2- to 3-fold increased levels of ASCIZ in
pre-leukemic Em-Myc pro-B/pre-B cells (Figure 4B). DYNLL1
levels in pre-malignant Em-Myc pro-B/pre-B cells were compa-
rable to those in malignant Em-Myc lymphomas (Figure 4C).
Interestingly, oncogenic MYC appeared to upregulate DYNLL1
predominantly in B cell precursors but not in mature splenic B
cells (from the same mice), which contained high DYNLL1
levels already in the absence of MYC (Figure 4C). Real-time
qPCR analyses confirmed that Dynll1 mRNA levels were upre-
gulated in pre-leukemic Em-Myc pro-B/-pre-B cells (Figure 4E),
albeit to a lower extent than upregulation at the protein level
(Figures 4A, 4C, and 4D). Asciz mRNA levels remained un-
changed (Figure 4E).
These data show that ASCIZ andMYC synergize to upregulate
DYNLL1 protein levels specifically during the early stages of B
cell differentiation that are vulnerable to Em-Myc-driven lympho-
magenesis. The stronger effect on protein, compared to mRNA
levels, suggests that MYC regulates DYNLL1 levels in these cells
by a combination of transcriptional and post-transcriptional
mechanisms. Finally, it should be noted that, in four independent
human Burkitt-lymphoma-derived cell lines, ASCIZ and DYNLL1
were present at high levels similar to those seen in mouse Em-
Myc pro-B/pre-B cells (Figures 4B and 4D). This suggests that
high levels of ASCIZ and DYNLL1 may also be important in hu-
man MYC-driven lymphomas.ors
Figure 4. ASCIZ-Dependent MYC-Driven
DYNLL1 Upregulation in Pre-leukemic B
Cell Precursors
(A) Western blot analysis of lysates (10 mg per
sample) of FACS-sorted combined pro-B and pre-
B cell fractions (B220+CD19+ IgM) from individual
mice with the genotypes indicated above, probed
for c-MYC, DYNLL1, BIM (EL/L), and actin.
(B)Western blot analysis of similar pro-B/pre-B cell
lysates probed for ASCIZ, c-MYC, and actin.
(C) Western blot of FACS-sorted pro-B/pre-B cells
(7.5 mg per sample) of non-Cre-expressing mice
and MACS-sorted splenic B cells (10 mg per sam-
ple) from the same mice, compared to lysates of
two independent Mb1-Cre Em-Myc lymphomas.
(D) Western blot ofMb1-Cre control,Mb1-Cre Em-
Myc, and Mb1-Cre Em-Myc DAsciz pro-B/pre-B
cells, compared to four different human Burkitt-
lymphoma-derived cell lines.
(E) Real-time qPCR analysis of Dynll1 and Asciz
mRNA levels relative to TbpmRNA levels in FACS-
sorted pro-B/pre-B cells from control and Em-Myc
mice.
Error bars represent mean ± SEM.ASCIZ Regulates MYC-Driven Lymphomagenesis via
DYNLL1 and BIM
Deletion of Asciz reversed the highly elevated DYNLL1 levels in
pre-cancerous Em-Myc B cell precursors to levels found in
normal control cells (Figure 4A), and this correlated with a
reduced lymphoma incidence inEm-MycDAscizmice (Figure 2A).
Therefore, we hypothesized that stage-specific DYNLL1 upregu-
lation is critical for MYC-driven lymphomagenesis. To directly
test this hypothesis, we generated a floxed Dynll1 allele for con-
ditional deletion in Em-Myc B cell precursors. Dynll1 contains
three exons, with the 89-amino-acid protein-coding sequence
located on exons 2 and 3 (Figure 5A). In theDynll1fl allele, we tar-
geted a region comprising the Dynll1 promoter and exons 1 and
2 for deletion to avoid interference with the Coq5 gene located
close to the 30 end of Dynll1 (Figure 5A). Without the promoter,
and in the absence of in-frame ATG codons within exons 3, it
is impossible for the recombined allele to yield any truncated
DYNLL1 protein product. Homozygous Dynll1fl/fl mice were
born at the expected Mendelian ratios and were indistinguish-
able from wild-type littermates. Western blot analysis confirmed
the absence of DYNLL1 protein in Dynll1fl/fl B lymphoid cells of
mice expressing Mb1-Cre (Figure 5B).
Mb1-Cre Dynll1-deletedmice had aB cell phenotype similar to
that ofMb1-Cre Asciz-deletedmice, with2-fold lower numbers
of pro-B/pre-B cells, 8-fold fewer immature B cells (p = 0.002),
and4-fold fewer splenic B cells (p < 0.0001) thanMb1-Cre con-
trol mice (Figure 5D). Similar to Asciz deletion (Figure 3B), loss of
DYNLL1 abrogated the abnormal increase in pro-B/pre-B cell
numbers in pre-malignant Em-Myc mice and led to a synergistic
>50-fold loss of immature B cells (p = 0.0032) compared to
control mice (Figure 5D). Importantly,Mb1-Cre-mediated Dynll1Cell Rdeletion also suppressed lymphoma development in Em-Myc
mice (Figure 5E; p = 0.0052), which is similar to the protective ef-
fect seen in Em-Myc DAsciz mice (Figure 2A). Thus, these data
indicate that ASCIZ exerts its essential role in MYC-driven lym-
phomagenesis predominantly through its molecular function as
a critical Dynll1 transcription factor.
Our data indicate that ASCIZ and DYNLL1 are critical for the
survival of pre-leukemic immature B cells in Em-Myc mice prior
to the acquisition of additional oncogenic lesions and subse-
quent progression to malignant lymphoma (Figures 3B, 3D,
and 5D). Upregulation of the pro-apoptotic protein BIM contrib-
utes to increased apoptotic cell death in premalignant Em-Myc B
lymphoid cells (and other MYC-overexpressing cell types), and
loss of Bim dramatically accelerates Em-Myc lymphoma devel-
opment (Egle et al., 2004). As ASCIZ and DYNLL1 appear to
prevent excessive BIM-mediated apoptosis of immature B cells
(Jurado et al., 2012b), we hypothesized that the protective
effect of Asciz (or Dynll1) deletion on lymphoma development
in Em-Myc mice may be due to increased BIM-mediated
apoptosis. To test this hypothesis, we intercrossed Mb1-Cre
Ascizfl/fl Em-Myc mice with Bim germline KO mice (Bouillet
et al., 1999). Remarkably, loss of even a single allele of Bim
completely reversed the protective effect of Asciz deletion on
the development of Em-Myc lymphoma (Figure 5F; p < 0.0001).
In addition, loss of Asciz had no significant protective effect
on the dramatically accelerated lymphoma development in Em-
Myc Bim/ mice. Taken together, these data indicate that
ASCIZ (and, presumably, also DYNLL1) exerts its effect on
MYC-driven lymphomagenesis through inhibition of BIM-medi-
ated apoptosis. It should be noted that BIM levels were not
elevated inMb1-Cre Asciz-deleted pro-B/pre-B cells comparedeports 14, 1488–1499, February 16, 2016 ª2016 The Authors 1493
Figure 5. Dynll1 Is Essential for MYC-Driven
Lymphomagenesis and Survival of Pre-
leukemic Em-Myc B Cell Precursors
(A) Targeting strategy to generate a conditional
Dynll1fl allele. Squares indicate exons, with pro-
tein-coding regions in exons 2 and 3 indicated in
black; triangles indicate LoxP sites. Dynll1 is
located close to the Coq5 gene, in converging
transcriptional direction.
(B) Western blot analysis of eight independent
lymphomas from Mb1-Cre Em-Myc and Mb1-Cre
Em-Myc Dynll1fl/fl mice probed with antibodies
for DYNLL1, c-MYC, and actin. Note that the
lower band in lane 8 is an uncharacterized cross-
reacting band. Additional panels are shown in
Figure S3B.
(C) FACS plots of B220+ CD43-gated bone
marrow cells of mice with the indicated genotypes,
with immature B cells highlighted by red boxes.
(D) Enumeration of B cell subsets in bone marrow
(one leg) and spleen cell suspensions of 8-week-
old Mb1-Cre control (n = 7–10), Mb1-Cre Dynll1-
deleted (n = 9–11), Mb1-Cre Em-Myc (n = 4), and
Mb1-Cre Em-Myc Dynll1-deleted (n = 8) mice. p
values were omitted from the graph for clarity. Pro-
B/pre-B cells: Em-Myc versus control, p = 0.0012;
Em-Myc versus DDynll1, p < 0.0001; Em-Myc
versus Em-Myc DDynll1, p = 0.0009. Immature B
cells: DDynll1 versus control, p = 0.002; Em-Myc
versus DDynll1, p = 0.003; DDynll1 versus Em-Myc
DDynll1, p = 0.0046; Em-Myc versus Em-Myc
DDynll1, p = 0.0002; Em-Myc DDynll1 versus
control, p = 0.0032. Spleen: DDynll1 versus con-
trol, p < 0.0001; DDynll1 versus Em-Myc DDynll1,
p = 0.0001; Em-Myc versus Em-Myc DDynll1, p =
0.0002; Em-Myc DDynll1 versus control, p <
0.0001. Gating strategies are shown in Figure S3A.
(E) Survival analysis of Mb1-Cre Dynll1+/+ Em-Myc
mice and Mb1-Cre Dynll1fl/fl Em-Myc mice. Note
that Mb1-Cre control and Mb1-Cre Em-Myc mice
shown in (D) and (E) are different individuals from
those shown in similar graphs in Figures 2 and 3.
(F) Survival curves for Mb1-Cre Em-Myc (red solid
line; n = 21; identical to Figure 2; included here for
comparison), Mb1-Cre Em-Myc DAsciz (blue solid
lines; n = 28; identical to Figure 2; included here
for comparison), Mb1-Cre Em-Myc Bim+/ (red
dashed line; n = 12), Mb1-Cre Em-Myc DAsciz
Bim+/ (blue dashed line; n = 15),Mb1-Cre Em-Myc
Bim/ (red stippled line; n = 3), and Mb1-Cre Em-
Myc DAsciz Bim/ (blue stippled line; n = 5) mice.
p values were omitted from the graph for clarity: Em-Myc DAsciz versus Em-Myc DAsciz Bim+/, p < 0.0001; Em-Myc Bim+/ versus Em-Myc DAsciz Bim+/,
p = 0.0001; Em-Myc DAsciz Bim+/ versus Em-Myc DAsciz Bim/, p = 0.0003.
Error bars represent mean ± SEM.
See also Figure S3.to the Mb1-Cre control (Figure 4A, lanes 1–4), in Asciz-deleted
Em-Myc pro-B/pre-B cells compared to the Em-Myc control (Fig-
ure 4A, lanes 5–11), or in Dynll1-deleted Em-Myc lymphomas
compared to control Em-Myc lymphomas. There were also
no consistent alterations in other BH3 protein family members
in Dynll1-deficient compared to control Em-Myc lymphomas
(Figure S3B). This indicates that any increased BIM activity
in ASCIZ- or DYNLL1-deficient B cell precursors is due to
post-translational effects, consistent with previous reports that1494 Cell Reports 14, 1488–1499, February 16, 2016 ª2016 The AuthDYNLL1 directly binds to BIM to inhibit its pro-apoptotic activity
locally at mitochondria or by sequestering BIM to microtubuli
(Puthalakath et al., 1999; Zhu et al., 2004).
ASCIZ Is Required for the Sustained Proliferation of
Established Em-Myc Lymphomas
To determine whether ASCIZ is required not only for lym-
phoma development but also for the malignancy of established
MYC-driven lymphomas, we crossed Ascizfl/fl Em-Myc mice toors
Rosa26-CreERT2 mice (CreER), enabling temporally controlled
Cre activation by tamoxifen treatment (Ventura et al., 2007). Cells
from B cell lymphomas that had developed in these mice were
then transplanted into healthy, congenic recipients. Upon emer-
gence of circulating donor-derived lymphoma cells, recipients
were treated with tamoxifen for 3 consecutive days or left un-
treated in the control group. In six of nine recipients transplanted
with four independent CreER Ascizfl/fl Em-Myc lymphomas,
tamoxifen treatment significantly delayed the time to lymphoma
relapse compared to matched untreated control mice trans-
planted with the same lymphoma (Figures 6A and 6B). One addi-
tional tamoxifen-treated mouse survived relapse-free until the
end of the observation period (Table S1) and was excluded
from Figure 6 as an outlier. Tamoxifen treatment of mice trans-
planted with CreER Asciz+/+ Em-Myc or CreER Ascizfl/+ Em-Myc
lymphomas (which retain at least one functional Asciz allele
upon Cre activation) did not improve survival compared to
lymphoma-matched untreated control recipients (Figures 6A
and 6B).
Continued monitoring of circulating tumor cells in transplant
recipients revealed a range of responses, including attenuated
lymphoma progression (Figure 6C) and transient remission
(Figure 6D) in tamoxifen-treated mice compared to untreated
lymphoma-matched controls. Interestingly, we found that all
relapsed CreER Ascizfl/fl Em-Myc lymphomas from tamoxifen-
treated mice had recombined only one of the two Ascizfl alleles
and retained the other intact coding sequence (Figure 6E, left
and middle panels). In control mice, the floxed Asciz allele was
efficiently and completely recombined—without any survival
advantage—when it was balanced by a wild-type Asciz allele
in CreER Ascizfl/+ Em-Myc lymphoma transplants (Figure 6C,
right panel). This demonstrates that the incomplete Cre-Lox
recombination in the relapsed Ascizfl/fl lymphomas was not due
to poor allele-specific Cre activity. These data indicate that com-
plete loss of ASCIZ confers a substantial growth disadvantage in
malignant Em-Myc lymphomas, which then results in the selec-
tion of Ascizfl/- heterozygous cells in relapsing tumors. In this
context, it is conceivable that the extended relapse-free survival
of the outlier (Table S1) may be due to complete Asciz deletion in
this particular transplant. In conclusion, given the rapid selection
against Asciz-deleted tumor cells, the observed survival benefits
(Figures 6A and 6B) are likely to significantly underestimate the
true benefit of complete Asciz removal on Em-Myc lymphoma
remission.
DISCUSSION
Here, we have shown that the ASCIZ-DYNLL1 axis plays a crit-
ical role in the development of MYC-driven lymphoma in the
widely studied Em-Myc mouse model. In addition, ASCIZ is
essential for the sustained proliferation of malignant MYC-driven
lymphomas, as shown by the improved survival upon deletion of
Asciz in established lymphomas, with potent negative selection
against Asciz null cells in relapsing tumors. ASCIZ and DYNLL1
seem to act by maintaining the survival of pre-leukemic B cell
precursors by restraining the pro-apoptotic activity of BIM,
akin to their role in normal B cell development. However, ASCIZ
and DYNLL1 seem to be even more crucial for B cell lymphomaCell Rdevelopment than for normal B cell development, as their loss re-
sults in a specific and dramatic synthetic-lethal interaction with
oncogenic MYC in pre-leukemic cells (Figures 3 and 5D).
A critical factor in the protective effect of Asciz or Dynll1 dele-
tions may be that DYNLL1 expression is dramatically increased
by oncogenic MYC levels, specifically during the B cell develop-
ment stages in which most Em-Myc lymphomas have their origin.
Thus, simply reversing the elevated DYNLL1 levels to approxi-
mately physiological levels found in normal pre-B cells (Fig-
ure 4A) is sufficient to prevent lymphoma development in
>80% of Mb1-Cre Asciz-deleted Em-Myc mice (Figure 3A). The
extent of MYC-driven upregulation of DYNLL1 in these cells ap-
pears to be due to a combination of transcriptional and post-
transcriptional effects. MYC binding can be readily detected at
the Dynll1 promoter (Sabo` et al., 2014; Walz et al., 2014). This
suggests that the 2-fold transcriptional upregulation of Dynll1
mRNA in pre-leukemic Em-Myc pro-B/pre-B cells may be due
to a direct effect of MYC on the Dynll1 promoter. It remains to
be determined how MYC leads to further upregulation of
DYNLL1 at the protein level in these cells and why this is not
observed in mature splenic Em-Myc B cells (Figure 4B).
The phenotypic similarities between Mb1-Cre Asciz-deleted
and Mb1-Cre Dynll1-deleted mice—in both the presence and
absence of the Em-Myc transgene—demonstrate that ASCIZ ex-
erts its role as an essential co-factor of MYC-driven lymphoma-
genesis through its molecular function as a Dynll1 transcription
factor. This adds to a growing body of work highlighting the
importance of ASCIZ-DYNLL1 interactions in the regulation of
fundamental cell functions and developmental processes (Gog-
golidou et al., 2014; Jurado et al., 2012a, 2012b; Rapali et al.,
2011; Zaytseva et al., 2014). An alternative proposed molecular
function for ASCIZ is that of an activator of the central DNA dam-
age response kinase ATM (Cremona and Behrens, 2014). This
has been invoked as an explanation for the development of
peripheral B cell lymphomas in Cd19-Cre Asciz-deleted mice
(Loizou et al., 2011). It should be noted that this increased B
cell lymphoma risk is unique to the Cd19-Cre Asciz line and
is not observed in our Cd23-Cre (Figure 1), Mb1-Cre, and Mx1-
Cre Asciz-deleted mouse lines (Jurado et al., 2012b) or in Vav-
Cre Asciz-deleted mice from the Behrens laboratory (Cremona
and Behrens, 2014). The floxed Asciz/Atmin alleles used in the
different laboratories are almost identical (resulting in deletion
of exon D, encoding 601 of 818 amino acid residues). Why
mature B cells from Cd19-Cre Asciz-deleted mice are prone to
increased genome instability, which then drives the development
of B cell lymphoma, remains enigmatic. Our results with Cd23-
Cre mice clearly show that ASCIZ is not intrinsically required
for ATM signaling, maintenance of genome stability, and tumor
suppression inmature B cells (Figure 1; Figure S1).Cd19-Cre be-
comes active at an earlier stage than Cd23-Cre, so a possible
explanation is that precocious deletion of Asciz somehow
causes indirect effects that manifest at the mature stage.
For example, the pre-B cell reductions in Cd19-Cre and Mb1-
Cre Asciz-deleted mice are quantitatively comparable (Jurado
et al., 2012b; Loizou et al., 2011), which suggests that, similar
to our Mb1-Cre Asciz-deleted mice (Figure 1B), BAFF (B cell-
activating factor from the tumor necrosis factor family) levels
may also be elevated in the Cd19-Cre Asciz mice. Elevatedeports 14, 1488–1499, February 16, 2016 ª2016 The Authors 1495
Figure 6. Impact of Acute Deletion of Asciz
in Malignant Em-Myc Lymphomas In Vivo
(A and B) Survival until tumor relapse (days post-
transplantation) of tamoxifen-treated mice com-
pared to matched untreated mice transplanted with
the same lymphomas. Numbers indicate the total
number of transplant recipients for each group,
with the number of independent experiments in
brackets. A tamoxifen-treated mouse that survived
relapse-free until the end of the observation period
was excluded from the analysis. Raw data are
shown in Table S1. The p values were calculated
using paired t test for matched samples (A) or un-
paired t test (B).
(C and D) FACS analysis of peripheral blood leu-
kocytes of tamoxifen-treated (top panels) and
matched untreated controls (bottom panels)
transplanted with the same lymphomas at the
indicated times before or after initiation of tamox-
ifen treatment. Donor-derived tumor cells are ho-
mozygous for Cd45.2, and recipients are Cd45.1/
Cd45.2 heterozygous.
(E) PCR analysis for Ascizfl recombination in lymph
nodes containing relapsed lymphomas dissected
at the observation endpoint from matched un-
treated or tamoxifen-treated mice transplanted
with the same tumors. The wild-type (wt) band in
one of the tumor samples reflects the presence of
recipient cells, which are Asciz+/+. del, deletion.
Error bars indicate mean ± SEM.
See also Table S1.
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BAFF extends the lifespan of peripheral B cells (Vincent et al.,
2013). This could conspire with other factors from the mixed ge-
netic background of the Cd19-Cre Asciz mice to allow the sur-
vival of old B cells under conditions that would otherwise activate
cell death programs, for example, in response to DNA damage.
Regardless of these considerations, the dramatic suppression of
Em-Myc lymphomagenesis caused by the absence of ASCIZ
(Figure 2A) is diametrically opposed to the marked acceleration
of Em-Myc lymphoma development in Atm/ mice (Shreeram
et al., 2006), which almost certainly rules out ATM-related contri-
butions to the phenotypes reported here.
In conclusion, our findings demonstrate that, rather than
acting as a tumor suppressor in mature B cells, ASCIZ is, in
fact, essential for MYC-driven development of lymphomas
derived from bone marrow B cell precursors. This function of
ASCIZ may be unique to MYC-driven cancers, as its deletion
in Im-Bcl6 mice (Figure 1) did not result in a comparable pro-
tective effect. ASCIZ and DYNLL1 are expressed in human
Burkitt lymphoma cell lines at a level similar to the critical
pre-leukemic B cell precursor stage in Em-Myc mice. In addi-
tion, the dramatic synthetic-lethal interaction between loss of
ASCIZ or DYNLL1 and high MYC levels in Em-Myc mice sug-
gests that the ASCIZ-DYNLL1 axis may be generally important
for the pathogenesis and clinical progression of MYC-driven
cancers beyond the mouse model. Inducible deletion of Asciz
in hematopoietic stem and precursor cells via Mx1-Cre in adult
mice has no major adverse effects on other white blood cell
compartments beyond B cells (Jurado et al., 2012b), and
within the B cell lineage, ASCIZ is required during develop-
ment but not for maintenance of mature B cells (Figure 1).
Thus, the specific synthetic-lethal effect of Asciz or Dynll1
deletion in the presence of oncogenic MYC levels indicates
that the ASCIZ-DYNLL1 axis may be a potential target for
the treatment of MYC-driven cancers.
EXPERIMENTAL PROCEDURES
Mice
All experimental procedures were approved by the St. Vincent’s Hospital An-
imal Ethics Committee. All mice were maintained on a pure C57BL/6 back-
ground and housed in specific pathogen free micro-isolators. Dynll1fl mice
were generated by TaconicArtemis on C57BL/6 background. Mice in survival
cohorts were culled when they were deemed to be ill by experienced animal
technicians blinded to their genotypes. Lymphoma-free mice that died from
other causes were excluded from analyses. Additional details are provided
in the Supplemental Experimental Procedures.
Flow Cytometry, B Cell Cultures, Western Blot Analysis, and ELISAs
FACS analyses were performed as described (Jurado et al., 2012b), using
conditions and antibodies indicated in the Supplemental Experimental Proce-
dures. Gating strategies are illustrated in Figure S2B, Figure 2B, and Fig-
ure S3A for Mb1-Cre Dynll1-deleted mice using Hardy staining (Hardy et al.,
1991).
B cell fractions were isolated using amagnetic-activated cell sorting (MACS)
bead B Cell Isolation Kit (Miltenyi Biotec) or sorting of mature splenic B cells
(Figure 1C; B220+ IgMlow IgDhigh) and bone marrow B cell precursors (Figure 4;
B220+ CD19+ IgM) using a FACSAria (BD Biosciences). B cells were cultured
for 3 days in the presence of CD40L, IL4, and LPS, followed by 1 hr treatment
with low salt medium or 2-Gy irradiation with 30-min recovery at 37C. Meta-
phase spreads were prepared from cultured cells treated with 0.1 mg/ml colce-
mid for 1 hr, scanned using a Zeiss Ikaros system, and scored by a clinicalCell Rcytogeneticist (M.W.). Human Burkitt-lymphoma-derived cell lines were
cultured as described elsewhere (Kelly et al., 2014).
Western blots were performed as described elsewhere (Jurado et al., 2010;
McNees et al., 2005), using the procedures and antibodies listed in the Supple-
mental Experimental Procedures. Serumwas collected from 8-week-old naive
mice and analyzed using a BAFF ELISA kit (R&D Systems), or at 13 days after
immunization of 4- to 6-month-old mice to determine antibody titers using
ELISA plates coatedwith NP2-BSA or NP14-BSA, and horseradish peroxidase
(HRP)-labeled goat anti-mouse IgG1 (Southern Biotech 1070-05).
Real-Time qPCR
RNAwas extracted from FACS-sorted pro-B/pre-B cells, and gene expression
was quantified on a Stratagene Mx3000P qPCR system using Brilliant II SYBR
green QPCRmaster mix (Agilent Technologies). Gene expression was normal-
ized to Tbp levels, which are known to be unaffected by MYC overexpression
in B cells (Sabo` et al., 2014; Walz et al., 2014).
Statistical Analysis
Statistical analysis was performed using GraphPad Prism software. The p
values were calculated by two-tailed unpaired Student’s t test, or paired t
test for matched samples, and Mantel-Cox test for survival analyses. Grouped
data represent the mean ± SEM.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures, and one table and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2016.01.012.
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